INSM
NASDAQ · Biotechnology
Insmed Inc
$114.41
+5.65 (+5.19%)
Performance
1D
+0.00%
1W
+4.66%
1M
+13.86%
3M
-15.10%
6M
+10.12%
1Y
-39.69%
YTD
-35.41%
Open$108.57
Previous Close$108.76
Day High$114.65
Day Low$107.29
52W High$212.75
52W Low$90.39
Volume—
Avg Volume4.92M
Market Cap23.86B
P/E Ratio—
EPS$-4.10
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$111.21
Above
SMA 200
$124.15
Below
RSI (14)
71.4
Overbought
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
31 analysts
Price Target
+25.3% upside
Current
$114.41
$114.41
Target
$143.40
$143.40
$91.17
$143.40 avg
$177.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 635.49M | 470.04M | 44.36B |
| Net Income | -1,337,988,428 | -890,672,770 | 1.08B |
| Profit Margin | -210.5% | -200.0% | 2.4% |
| EBITDA | -1,300,260,720 | -913,644,736 | 2.00B |
| Free Cash Flow | — | — | 843.11M |
| Rev Growth | +35.2% | +35.2% | +19.4% |
| Debt/Equity | 0.99 | 0.99 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |